The 4 analysts offering 12-month price forecasts for Corcept Therapeutics Inc have a median target of 24.00, with a high estimate of 35.00 and a low estimate of 16.00. The median estimate represents a +14.83% increase from the last price of 20.90.
The current consensus among 4 polled investment analysts is to Buy stock in Corcept Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.21
Reporting Date Feb 24
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.